| Product NDC: | 0591-0339 |
| Proprietary Name: | Diclofenac Sodium |
| Non Proprietary Name: | Diclofenac Sodium |
| Active Ingredient(s): | 75 mg/1 & nbsp; Diclofenac Sodium |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, DELAYED RELEASE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0591-0339 |
| Labeler Name: | Watson Pharma, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA075185 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 19981113 |
| Package NDC: | 0591-0339-05 |
| Package Description: | 12 BOTTLE, PLASTIC in 1 BOX (0591-0339-05) > 500 TABLET, DELAYED RELEASE in 1 BOTTLE, PLASTIC |
| NDC Code | 0591-0339-05 |
| Proprietary Name | Diclofenac Sodium |
| Package Description | 12 BOTTLE, PLASTIC in 1 BOX (0591-0339-05) > 500 TABLET, DELAYED RELEASE in 1 BOTTLE, PLASTIC |
| Product NDC | 0591-0339 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Diclofenac Sodium |
| Dosage Form Name | TABLET, DELAYED RELEASE |
| Route Name | ORAL |
| Start Marketing Date | 19981113 |
| Marketing Category Name | ANDA |
| Labeler Name | Watson Pharma, Inc. |
| Substance Name | DICLOFENAC SODIUM |
| Strength Number | 75 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Cyclooxygenase Inhibitors [MoA],Decreased Prostaglandin Production [PE],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC] |